Merck, Neuromed Discontinue N-Type Calcium Channel Blocker For Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies will continue a joint research effort to deliver a “best in class” candidate, Neuromed CEO Gallen tells “The Pink Sheet” DAILY.